Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
Press Release – No. 2 / 2025
See the original post:
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
Ipsen – December 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – Half year statement – 2024 12 31
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Go here to see the original:
Ipsen - Half year statement - 2024 12 31
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco.A live webcast of the presentation will be accessible on the Investors page of the Company’s website at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.In addition, Galapagos management will host a sell-side analyst breakfast in San Francisco on Tuesday, January 14, 2025 at 8:00 am PT. Analysts interested in attending should reach out the Galapagos Investor Relations team at ir@glpg.com.
Original post:
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference, which is being held in San Francisco from January 13-16, 2025. The Company’s presentation will be on Wednesday, January 15 at 2:15 pm ET / 11:15 am PT.
See the article here:
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m. PT.
The rest is here:
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression
The rest is here:
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced a notice to shareholders regarding U.K. disclosure requirements.
See the original post:
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today provided corporate updates and key objectives for 2025.
Continue reading here:
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.